Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
The following is a summary of the Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript:Financial Performance:Daiichi Sankyo's FY 2023 revenue increased 25.3% year-on-year to ¥1.601
moomoo AI12:55 ET · Conference Call
The Nikkei Average in the backstage started with a 297 yen increase, and Daiichi Sankyo and Mitsui E&S are high
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 37926.06; +297.58TOPIX; 2681.69; +18.16 [Backward Closer Overview] The Nikkei Average in the back was 37926.06 yen, 297.58 yen higher than the previous day, and started by expanding the range of gains from the previous closing (37780.35 yen). Nikkei 225 futures during lunchtime rose in the range of 37740 yen to 38,000 yen. The dollar and yen depreciated by about 40 yen from around 9:00 a.m. to 1 dollar = 156.00-10 yen
Fisco JapanApr 26 00:01 ET
Daiichi Sankyo and others announced stock buybacks on 4/25
The stocks that announced share acquisition quota settings on 4/25 (Thursday) are as follows <4568>Daiichi Sankyo 55 million shares (2.9%) 200 billion yen (24/4/26-25/1/15) <6702>Fujitsu 150 million shares (8.2%) 180 billion yen (24/5/1-25/3/31) <9531>East Gas 17 million shares (4.2%) 40 billion yen (24/5/7-25/3/31) <430
Fisco JapanApr 25 18:04 ET
Daiichi Sankyo temporarily rose by over 5%, supported by stock buybacks up to 20 billion yen and dividend increase plans for the current fiscal year
Daiichi Sankyo was bought in the back market, and there was an increase of over 5% at one point compared to the previous day. Along with the announcement of consolidated financial results for the fiscal year ending March 24 at 1:00 p.m. on the 25th, it was announced that the total number of shares acquired is 55 million shares (2.87% of the total number of issued shares excluding treasury stock) and the total acquisition amount is 20 billion yen as an upper limit. At the same time, a plan to increase the annual dividend for the fiscal year ending March 25 to 60 yen with a 10 yen increase from the previous fiscal year was also shown, and it seems that it was a support material for stock prices.
MinkabuApr 25 01:56 ET
Vincerx in Selloff After Early-stage Data for Cancer Therapy
Seeking AlphaApr 9 08:54 ET
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
British drugmaker AstraZeneca (AZN.L, AZN.ST) and Japanese partner Daiichi Sankyo scored new regulatory wins for their jointly developed cancer treatment Enhertu in the US, according to a Monday release.
MT NewswiresApr 8 04:35 ET
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval
AstraZeneca (AZN.L, AZN.ST) secured accelerated approval for its antibody drug conjugate Enhertu, co-developed with Daiichi Sankyo (D4S.F), for treating adult patients with unresectable or metastatic HER2-positive solid tumors in the US.
MT NewswiresApr 8 02:49 ET
AstraZeneca's Enhertu Granted Approval for HER-2 Positive Tumor-agnostic Indications
Seeking AlphaApr 5 16:14 ET
FDA Accepts Daiichi Sankyo-AstraZeneca's Breast Cancer Therapy for Review
Seeking AlphaApr 2 08:16 ET
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
Yahoo FinanceMar 4 02:00 ET
Pfizer, Gilead, Roche Seen Benefitting the Most From Antibody-drug Conjugates
Seeking AlphaMar 2 14:00 ET
Daiichi Sankyo-AstraZeneca Gets BLA Approved for Lung Cancer Therapy in the U.S.
Seeking AlphaFeb 19 07:36 ET
DATO-DXD jointly developed by Daiichi Sankyo/AstraZeneca (AZN.US)
On February 19, Daiichi Sankyo/AstraZeneca (AZN.US) jointly announced that its dato-DXD biological product license application (BLA) was accepted by the FDA for use in adult patients with locally advanced or metastatic non-squamous NSCLC who have previously received systemic treatment. The PDUFA date is December 20, 2024.
Zhitong FinanceFeb 19 06:59 ET
Pharma Giants Turn to China in Search of Targeted Cancer Drugs
Seeking AlphaFeb 4 12:00 ET
Daiichi Sankyo Reports 9M Results
Seeking AlphaFeb 1 14:27 ET
Merck Posts Q4 Beat as Keytruda Outperforms
Seeking AlphaFeb 1 07:28 ET
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On March 28th, 2024 With 0.264 USD Dividend Per Share
February 1st - $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ is trading ex-dividend on March 28th, 2024. Shareholders of record on March 31st, 2024 will receive 0.264 USD dividend per share on June 2
moomoo NewsJan 31 19:40 ET
AstraZeneca Says Enhertu Application for HER2-Positive Solid Tumors Slated for FDA Priority Review
AstraZeneca (AZN) and Daiichi Sankyo said Monday their supplemental biologics license application for Enhertu was granted priority review by the US Food and Drug Administration.
MT NewswiresJan 29 08:40 ET
AstraZeneca/ Daiichi Win FDA Priority Review for Enhertu Label Expansion
Accepting the sBLA for priority review, the regulator has issued May 30, 2024, as the Prescription Drug User Fee Act (PDUFA) date for its decision.
Seeking AlphaJan 29 06:46 ET
What's Going On With Pfizer Stock Today?
Pfizer Inc (NYSE:PFE) is set to announce its fourth quarter 2023 earnings next week on 30th January. The analysts expect the US pharma giant to report an EPS loss of $(0.22) and revenues of $14.25 bil
BenzingaJan 25 09:26 ET
No Data
No Data